Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality.

Mehta, Puja; Titanji, Boghuma K

Mehta, Puja; Titanji, Boghuma K.

Mehta P; Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK; Department of Rheumatology, University College London Hospital NHS Trust, London, UK.
Titanji BK; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: boghuma.kabisen.titanji@emory.edu.

Lancet ; 400(10349): 338-339, 2022 07 30.

Article in English | MEDLINE | ID: covidwho-1967457

Subject(s)

Azetidines; COVID-19 Drug Treatment; Artificial Intelligence; Azetidines/therapeutic use; Humans; Purines; Pyrazoles; Sulfonamides

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Year: 2022 Document Type: Article Affiliation country: S0140-6736(22)01295-8

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google